NPC1 and hereditary disease: Engineered NPC1 mRNA with optimized codons and N1-methylpseudouridine base modification has been demonstrated to correct the cholesterol transport defect in NP-C1 patient cells, confirming the promising potential of engineered mRNA in the treatment of inherited disease (Furtado et al., 2022).